Cellular reprogramming to enable the precise and scalable manufacturing of human cells for therapeutic applications

In this presentation, our Senior Scientist, Dr Alex Davenport, discusses how cellular reprogramming enables the precise and scalable manufacturing of human cells for therapeutic applications. Davenport highlights how having access to a reliable and consistent source of human cells is a potential game changer for cell therapies.

Presenting key examples from external partners and collaborators, Davenport demonstrates how bit.bio’s core technology, opti-ox™, has been applied to created megakaryocytes, myogenic precursors and astrocytes.

Watch now to discover how bit.bio’s core technology:

• provides a solution to the bottlenecks of current cell therapies
• unlocks the potential of iPSCs for therapeutic applications
• has been applied to generate functional cells which have been validated in vivo